A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

Agents that target B-cell receptor (BCR) signaling in lymphoid malignancies including idelalisib (GS-1101) and fostamatinib which inhibit the delta isoform of PI3 kinase (PI3Kd) and spleen tyrosine kinase (Syk) respectively have shown significant clinical activity. By disrupting B-cell signaling pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011593/
https://ncbi.nlm.nih.gov/pubmed/24659719
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados